- Home
- HCI vs HCM Comparison
HCI vs HCM Comparison
Compare HCI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | HCM |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | Hong Kong |
| Employees | 594 | 1796 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HCI | HCM |
|---|---|---|
| Price | $163.17 | $10.83 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $230.00 | $13.75 |
| AVG Volume (30 Days) | ★ 133.6K | 59.7K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.44 | $20.60 |
| Revenue Next Year | $7.67 | $15.62 |
| P/E Ratio | $9.97 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.37 | $10.40 |
| 52 Week High | $210.50 | $19.50 |
Technical Indicators
Market Signals| Indicator | HCI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 31.56 |
| Support Level | $148.86 | N/A |
| Resistance Level | $169.48 | $15.59 |
| Average True Range (ATR) | 4.75 | 0.32 |
| MACD | 1.00 | 0.04 |
| Stochastic Oscillator | 87.46 | 29.41 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.